142 active trials 85 recruiting 6 Phase 3 83 sponsors 31 changes in 30 days
| Early Phase 1 | 1 | |
| Phase 1 | 27 | |
| Phase 1/2 | 13 | |
| Phase 2 | 46 | |
| Phase 3 | 6 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT04064060 | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other… | Celgene | Recruiting | 2026-07-01 |
| NCT05198960 | AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic… | University Hospital, Brest | Recruiting | 2026-03-20 |
| NCT06740916 | Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients… | Siriraj Hospital | Recruiting | 2024-12-27 |
| NCT02521493 | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or… | Children's Oncology Group | Active, Not Recruiting | 2026-08-19 |
| NCT06468033 | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | PharmaEssentia | Active, Not Recruiting | 2026-08-13 |
| NCT04717414 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With… | Celgene | Active, Not Recruiting | 2026-07-16 |
| Phase 2 | ||||
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study… | National Cancer Institute (NCI) | Recruiting | 2026-08-27 |
| NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed… | National Cancer Institute (NCI) | Recruiting | 2026-08-27 |
| NCT04493164 | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or… | M.D. Anderson Cancer Center | Recruiting | 2026-08-25 |
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative… | National Cancer Institute (NCI) | Recruiting | 2026-08-19 |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With… | Fred Hutchinson Cancer Center | Recruiting | 2026-08-19 |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic… | University of Washington | Recruiting | 2026-08-19 |
| NCT02727803 | Personalized NK Cell Therapy in CBT | M.D. Anderson Cancer Center | Recruiting | 2026-07-30 |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and… | Fred Hutchinson Cancer Center | Recruiting | 2026-07-29 |
| NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in… | Fred Hutchinson Cancer Center | Recruiting | 2026-07-22 |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Masonic Cancer Center, University of Minnesota | Recruiting | 2026-07-06 |
| NCT05074355 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative… | University Health Network, Toronto | Recruiting | 2026-07-06 |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the… | City of Hope Medical Center | Recruiting | 2026-06-29 |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Masonic Cancer Center, University of Minnesota | Recruiting | 2026-06-25 |
| NCT03589729 | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in… | M.D. Anderson Cancer Center | Recruiting | 2026-05-22 |
| NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium… | Icahn School of Medicine at Mount Sinai | Recruiting | 2026-05-06 |
| NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | University of Manitoba | Recruiting | 2026-04-22 |
| NCT06063486 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of… | University of Southern California | Recruiting | 2026-03-27 |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based… | Center for International Blood and Marrow Transplant Research | Recruiting | 2026-03-17 |
| NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of… | University of Washington | Recruiting | 2026-03-16 |
M.D. Anderson Cancer Center (12) · City of Hope Medical Center (8) · National Cancer Institute (NCI) (8) · Incyte Corporation (6) · Fred Hutchinson Cancer Center (5) · University Hospital, Angers (4) · Assiut University (3) · Dana-Farber Cancer Institute (3) · University Hospital, Bordeaux (3) · University Hospital, Brest (3)